Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1981 Aug;20(2):231–234. doi: 10.1128/aac.20.2.231

Biliary excretion of moxalactam.

O V Martinez, J U Levi, A Livingstone, T I Malinin, R Zeppa, D Hutson, N Einhorn
PMCID: PMC181668  PMID: 6456690

Abstract

The biliary excretion of moxalactam was studied in 11 postsurgery patients who had indwelling T-tubes inserted in their common bile ducts. Peak levels of moxalactam in the bile reached mean levels of 33.7 +/- 11.1 and 173.7 +/- 67.0 micrograms/ml 2 h after intravenous administration of a single 500- or 2,000-mg dose, respectively. In 5 of the 10 patients given the 2,000-mg dose, peak moxalactam concentrations in the bile were 2 to 12 times higher than simultaneous serum levels, but considerable variation in the biliary excretion of moxalactam was observed among the individual patients.

Full text

PDF
231

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergan T., Dobloug I., Liavåg I. Bacterial isolates in cholecystitis and cholelithiasis. Scand J Gastroenterol. 1979;14(5):625–631. doi: 10.3109/00365527909181401. [DOI] [PubMed] [Google Scholar]
  2. Chetlin S. H., Elliott D. W. Preoperative antibiotics in biliary surgery. Arch Surg. 1973 Aug;107(2):319–323. doi: 10.1001/archsurg.1973.01350200179037. [DOI] [PubMed] [Google Scholar]
  3. Delgado D. G., Brau C. J., Cobbs C. G., Dismukes W. E. In vitro activity of LY127935, a new 1-oxa cephalosporin, against aerobic gram-negative bacilli. Antimicrob Agents Chemother. 1979 Dec;16(6):864–868. doi: 10.1128/aac.16.6.864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Delikaris P. G., Michail P. O., Klonis G. D., Haritopoulos N. C., Golematis B. C., Dreiling D. A. Biliary bacteriology based on intraoperative bile cultures. Am J Gastroenterol. 1977 Jul;68(1):51–55. [PubMed] [Google Scholar]
  5. England D. M., Rosenblatt J. E. Anaerobes in human biliary tracts. J Clin Microbiol. 1977 Nov;6(5):494–498. doi: 10.1128/jcm.6.5.494-498.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fass R. J. In vitro activity of LY127935. Antimicrob Agents Chemother. 1979 Oct;16(4):503–509. doi: 10.1128/aac.16.4.503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Goswitz J. T. Bacteria and biliary tract disease. Am J Surg. 1974 Nov;128(5):644–646. doi: 10.1016/s0002-9610(74)80019-x. [DOI] [PubMed] [Google Scholar]
  8. Jorgensen J. H., Crawford S. A., Alexander G. A. Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria. Antimicrob Agents Chemother. 1980 May;17(5):901–904. doi: 10.1128/aac.17.5.901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jorgensen J. H., Crawford S. A., Alexander G. A. In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli. Antimicrob Agents Chemother. 1980 Jun;17(6):937–942. doi: 10.1128/aac.17.6.937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Levi J. U., Livingstone A. S., Martinez O. V., Zeppa R., Malinin T., Hutson D. G., Einhorn N. C. Biliary concentrations of cefamandole and its use in biliary tract surgery. Scand J Infect Dis Suppl. 1980;Suppl 25:55–57. [PubMed] [Google Scholar]
  11. Logan M. N., Wise R., Grimley R. P. Biliary levels of cefoxitin. J Antimicrob Chemother. 1979 Sep;5(5):620–621. doi: 10.1093/jac/5.5.620. [DOI] [PubMed] [Google Scholar]
  12. Ratzan K. R., Baker H. B., Lauredo I. Excretion of cefamandole, cefazolin, and cephalothin into T-tube bile. Antimicrob Agents Chemother. 1978 Jun;13(6):985–987. doi: 10.1128/aac.13.6.985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ratzan K. R., Ruiz C., Irvin G. L., 3rd Biliary tract excretion of cefazolin, cephalothin, and cephaloridine in the presence of biliary tract disease. Antimicrob Agents Chemother. 1974 Oct;6(4):426–431. doi: 10.1128/aac.6.4.426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sales J. E., Sutcliffe M., O'Grady F. Cephalexin levels in human bile in presence of biliary tract disease. Br Med J. 1972 Aug 19;3(5824):441–443. doi: 10.1136/bmj.3.5824.441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Severn M., Powis S. J. Biliary excretion and tissue levels of cefuroxime. A study in eleven patients undergoing cholecystectomy. J Antimicrob Chemother. 1979 Mar;5(2):183–188. doi: 10.1093/jac/5.2.183. [DOI] [PubMed] [Google Scholar]
  16. Strachan C. J., Black J., Powis S. J., Waterworth T. A., Wise R., Wilkinson A. R., Burdon D. W., Severn M., Mitra B., Norcott H. Prophylactic use of cephazolin against wound sepsis after cholecystectomy. Br Med J. 1977 May 14;1(6071):1254–1256. doi: 10.1136/bmj.1.6071.1254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Trager G. M., White G. W., Zimelis V. M., Panwalker A. P. LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity. Antimicrob Agents Chemother. 1979 Sep;16(3):297–300. doi: 10.1128/aac.16.3.297. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES